Attorney Docket No.: PB60179USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HUGHES, Ian *et al*. Confirmation No.: 4596 Serial No.: 10/550,939 Group Art Unit: 1797

Filing Date: September 28, 2005 Examiner: HOBBS, Michael L.

For: Microfluidic System

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR §1.97.

- Copies of the references are attached. Copies of the other references were submitted in parent application Serial No. __. (37 CFR §1.98(d)). A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached Form PTO-1449, and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. (37 CFR §1.97(b)). OR The Information Disclosure Statement submitted herewith is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 CFR §1.114. (37 CFR §1.97(b)(4)).
- B. [X] The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in §1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
 - (1) a final Office Action under §1.113 or
 - (2) a Notice of Allowance under §1.311, whichever occurs first.

	[]	Information Disclosure States	t each item of information contained in this ment was cited in a communication from a foreign foreign application not more than three months ment.
	[X]		pay the fee set forth in 37 CFR §1.17(p) for Disclosure Statement under §1.97(c) (\$180.00).
C.	[]	final Office Action under §1. whichever occurs first, but be	Statement transmitted herewith is being filed after and the statement of the issue fee. Also enclosed is earch Report which issued on International
In acco	ordance	with the requirements of 37 C	FR §1.97(d):
	[]	Information Disclosure States	t each item of information contained in this ment was cited in a communication from a foreign foreign application not more than three months ment.
	OR		
	[]	Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; and	
	[]	The petition fee set forth in §	1.17(i)(1) (\$180.00) is submitted herewith.
 [X] Please charge any required fees to Deposit Account No. <u>07-13</u> [] A duplicate copy of this paper is attached. 		<u></u>	
			Respectfully submitted,
			/J. MICHAEL STRICKLAND/
			J. Michael Strickland Attorney of Record Registration No. 47,115
_		9, 2009	
	ner No. SmithK		
GlaxoSmithKline Corporate Intellectual Property			
		- ▼	

Attorney Docket No.: PB60179USw

Five Moore Drive, P.O. Box 13398

Telephone: (919) 483-9024

Facsimile: (919) 483-7988

Research Triangle Park, NC 27709-3398

Page 2 of 2